Filing Summary: Fresenius Medical Care AG & Co. KGaA
Business Context and Reporting Period
This Form 6-K, dated May 3, 2017, reports the first quarter financial results for the period ending March 31, 2017. The filing serves to distribute a press release and corresponding financial figures to the U.S. Securities and Exchange Commission.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached exhibits (Exhibit 99.1 and Exhibit 99.2) referenced in the document.
The Company utilizes the following non-GAAP financial measures to supplement IFRS reporting:
- EBITDA (Operating income excluding interest, taxes, depreciation, and amortization)
- Delivered operating income (Earnings before interest and taxes)
- Free cash flow
Material Changes
The filing text does not disclose specific material changes or comparative data versus the prior period. Investors must refer to the attached press release for year-over-year performance analysis.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, and unusual items are not detailed in the cover letter of this Form 6-K. The document states that the attached press release contains non-GAAP measures intended to enhance understanding of current performance and future prospects. Reconciliations between non-GAAP and IFRS measures are included in the exhibits.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2017 revenue and profit figures.
- Examine Exhibit 99.2 for detailed financial statements and cash flow data.
- Verify the reconciliation of non-GAAP measures (EBITDA, delivered operating income, free cash flow) to IFRS standards as presented in the exhibits.
- Check the press release for any updated full-year guidance or specific risk factors mentioned by management.